Monica Fay

Comparative Effectiveness Research of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of a Large Health Insurance Claims Database

Aaron Boster, Jacqueline Nicholas, Ning Wu et al. · Neurology and Therapy · 2017 · 78 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis

Sander Yermakov, Matthew Davis, Michaela Calnan et al. · Journal of Medical Economics · 2015 · 57 citations · Full text

Pharmacy, Pharmacoeconomics, Health Services Research +16

Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States

Josephine Mauskopf, Monica Fay, Ravi Iyer et al. · Journal of Medical Economics · 2015 · 32 citations

Pharmacy, Neurology, Pharmacoeconomics +17

Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States

L Hernandez, Shien Guo, Elizabeth Kinter et al. · Journal of Medical Economics · 2016 · 28 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data

Jacqueline Nicholas, Aaron Boster, Ning Wu et al. · PharmacoEconomics - Open · 2017 · 22 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17